ARGENX (ARGX) Company Report

Analyst Coverage

Research analysts who have asked questions during ARGENX earnings calls.

Derek Archila

Wells Fargo

6 questions for ARGX

Also covers: APLS, ARVN, ASND +9 more

Rajan Sharma

Goldman Sachs Group, Inc.

6 questions for ARGX

Also covers: AUTL, AZN, CVAC +6 more

Samantha Semenkow

Citigroup Inc.

6 questions for ARGX

Also covers: ALLO, BEAM, CPRX +7 more

Tazeen Ahmad

Bank of America

6 questions for ARGX

Also covers: ACAD, ALNY, APLS +20 more

Victor Floch

BNP Paribas

6 questions for ARGX

Yaron Werber

TD Cowen

6 questions for ARGX

Also covers: ALEC, AMGN, ASND +14 more

Douglas Tsao

H.C. Wainwright & Co.

5 questions for ARGX

Also covers: ALKS, APLS, ARQT +19 more

Yatin Suneja

Guggenheim Partners

5 questions for ARGX

Also covers: ACAD, AXSM, CLDX +10 more

Amy Li

Jefferies Financial Group Inc.

4 questions for ARGX

Also covers: IRWD, JAZZ, MDGL

Gavin Clark-Gartner

Evercore ISI

4 questions for ARGX

Also covers: ACRS, ASND, CMPS +11 more

Myles Minter

William Blair & Company

4 questions for ARGX

Also covers: ALEC, ARCT, AXSM +11 more

Thomas Smith

Leerink Partners

4 questions for ARGX

Also covers: ACRS, CLDX, CNTB +5 more

Xian Deng

Berenberg

4 questions for ARGX

Also covers: GLPG, GMAB

Alexander Thompson

Stifel

3 questions for ARGX

Also covers: ACRS, ASND, CRNX +4 more

Alex Thompson

Stifel Financial Corp.

3 questions for ARGX

Also covers: ASND, CRNX, KYMR +1 more

Andy Chen

Wolfe Research, LLC

3 questions for ARGX

Also covers: CRNX, IMVT, INCY +7 more

Charles Pitman-King

Barclays

3 questions for ARGX

Also covers: GRFS

Danielle Brill

Truist Securities

3 questions for ARGX

Also covers: ACAD, BBIO, HRMY +5 more

James Gordon

JPMorgan Chase & Co.

3 questions for ARGX

Also covers: AZN, GRFS, GSK

Joel Beatty

Baird

3 questions for ARGX

Also covers: ACAD, ALKS, AMLX +11 more

Suzanne van Voorthuizen

Kempen & Co

3 questions for ARGX

Also covers: BNTX, GMAB, HOOK +3 more

Vikram Purohit

Morgan Stanley

3 questions for ARGX

Also covers: ABSI, ARQT, ASND +11 more

Akash Tewari

Jefferies

2 questions for ARGX

Also covers: ALKS, APLS, ARVN +15 more

Cassie Yuan

RBC Capital Markets

2 questions for ARGX

Jacob Mekhael

KBC Securities

2 questions for ARGX

Also covers: AUTL, GLPG

Leland Gershell

Oppenheimer & Co. Inc.

2 questions for ARGX

Also covers: ASND, CAPR, CASI +13 more

Manos Mastorakis

Deutsche Bank

2 questions for ARGX

Also covers: BNTX, GLPG

Matthew Phipps

William Blair

2 questions for ARGX

Also covers: ABBV, AGEN, AMGN +8 more

Morgan

Morgan Stanley

2 questions for ARGX

Nick

Virtue Capital

2 questions for ARGX

Also covers: ARE, YI

Richard Vosser

JPMorgan Chase & Co.

2 questions for ARGX

Also covers: AZN, MOLN, NVO +2 more

Brian Conley

Leerink Partners

1 question for ARGX

Charles Pitman

Barclays PLC

1 question for ARGX

Also covers: GRFS, SOAGY

David Nierengarten

Wedbush Securities

1 question for ARGX

Also covers: ITOS, KNSA, NUVB +4 more

Maddalena Delma Caiati

Guggenheim

1 question for ARGX

Mehdi Goudarzi

Truist Securities

1 question for ARGX

Also covers: EDIT, NTLA, RARE +1 more

Nat Charoensook

Leerink Partners

1 question for ARGX

Also covers: IMUX, VKTX

Sean Laaman

Morgan Stanley & Co.

1 question for ARGX

Also covers: ACAD, AXSM, BGNE +8 more

Latest news

Recent press releases and 8-K filings for ARGX.

ARGENX Announces FDA Acceptance of Priority Review for VYVGART in Seronegative gMG

ARGX

Product Launch

New Projects/Investments

ARGENX SE announced on January 13, 2026, that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART (efgartigimod alfa-fcab).
The sBLA is for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG).
The PDUFA target action date for the FDA's decision is May 10, 2026.
This application is supported by data from the Phase 3 ADAPT SERON study, which met its primary endpoint, demonstrating a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score compared to placebo.

2 days ago

6-K

argenx Reports Preliminary Q4 and Full-Year 2025 Results, Outlines 2026 Strategic Priorities, and Announces Leadership Changes

ARGX

Earnings

Guidance Update

Management Change

argenx reported preliminary full-year 2025 global product net sales of $4.15 billion, reflecting 90% year-over-year growth, with $1.29 billion in fourth-quarter sales.
The company anticipates four registrational readouts in 2026, including the first for empasiprubart, and expects to launch AChR-Ab seronegative gMG by the end of 2026 if approved.
By the end of 2026, argenx expects to have a total of 10 clinical-stage molecules in its pipeline, with three new molecules entering Phase 1 studies during the year.
Karen Massey is set to transition from Chief Operating Officer to Chief Executive Officer and Executive Director, while current CEO Tim Van Hauwermeiren will become non-Executive Director and Chairman of the Board, subject to shareholder approval on May 6, 2026.

3 days ago

6-K

argenx Reports Strong Q4 2025 VYVGART Sales and Pipeline Progress

ARGX

Earnings

Product Launch

New Projects/Investments

argenx reported strong financial performance for Q4 2025, with VYVGART sales reaching approximately $1.3 billion, representing a 14% increase from the previous quarter. The company almost doubled its business in 2025 compared to 2024 and achieved structural profitability in 2025.
The company is actively expanding VYVGART's market, with a supplemental Biologics License Application (sBLA) submitted for seronegative Myasthenia Gravis (MG), targeting potential approval and launch in the second half of 2026. Additionally, ocular MG data is anticipated in Q1 2026.
argenx is advancing a robust pipeline, with 10 molecules in clinical development and four in Phase III. Key upcoming data readouts include autoimmune myositis in Q3 2026, ITP in Q4 2026, and EMPA in MMN in Q4 2026.
The company plans to continue increasing its R&D investment to fully develop its growing late-stage and early-stage pipeline, aligning with its strategic agenda as a growth and innovation company.

3 days ago

Transcript

argenx Highlights Strong VYVGART Growth and Pipeline Progress at J.P. Morgan Healthcare Conference

ARGX

Revenue Acceleration/Inflection

New Projects/Investments

Product Launch

argenx reported Q4 2025 VYVGART sales of $1.3 billion, a 14% increase from the previous quarter, nearly doubling its business in 2025 compared to 2024, and achieving structural profitability in 2025.
The company is on track to impact 50,000 patients by 2030 through 10 labeled indications and aims to have five new molecules in Phase 3 by 2030. Currently, 19,000 patients are on VYVGART, and 10 registration trials are running in 2026.
Key upcoming data readouts for efgartigimod include ocular MG in Q1 2026, myositis in Q3 2026, and ITP in Q4 2026. The sBLA for seronegative MG patients was submitted, with potential approval in H2 2026.
VYVGART achieved blockbuster status in CIDP in Q3 2025 and is the number one prescribed biologic in MG, driving 60% of biologic growth in that indication. The company plans to continue expanding the market for VYVGART in MG and CIDP, with new indications like autoimmune myositis and Sjögren's disease.
argenx is advancing its pipeline with 10 molecules in clinical development, including four in Phase 3, and is developing next-gen FcRn molecules like ARGX-213 and ARGX-124, as well as new molecules through partnerships. The company expects its investment in R&D to continue to increase as it advances its pipeline.

3 days ago

Transcript

argenx Reports Strong 2025 Performance and Outlines 2026 Strategic Priorities at J.P. Morgan Healthcare Conference

ARGX

Earnings

Guidance Update

New Projects/Investments

argenx reported strong 2025 financial results, with VYVGART sales reaching $1.3 billion in Q4 2025, a 14% increase quarter-over-quarter, and the business nearly doubling in 2025 compared to 2024. The company also achieved structural profitability in 2025.
The company is advancing towards its Vision 2030 goal of impacting 50,000 patients across 10 labeled indications and having five new molecules in Phase 3, with 19,000 patients currently on VYVGART and 10 registration trials underway in 2026.
Significant upcoming data readouts include efgartigimod for Ocular MG in Q1 2026, Myositis in Q3 2026, and ITP in Q4 2026. Empasiprubart (empa) is expected to have MMN data in Q4 2026. The company anticipates increased R&D investment to support its expanding pipeline.

3 days ago

Transcript

ARGENX Announces Leadership Transition

ARGX

CEO Change

Board Change

Management Change

argenx SE announced a leadership transition on January 5, 2026, with changes subject to shareholder approval at the Annual General Meeting on May 6, 2026.
Karen Massey, current Chief Operating Officer, is set to become the new Chief Executive Officer and Executive Director.
Tim Van Hauwermeiren, the current Chief Executive Officer, will transition to non-Executive Director and Chairman of the Board of Directors, succeeding Peter Verhaeghe who is retiring.

Jan 5, 2026, 12:26 PM

6-K

ARGENX Discontinues UplighTED Studies for Efgartigimod SC in Thyroid Eye Disease

ARGX

New Projects/Investments

ARGENX SE announced the discontinuation of its Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED).
The decision to stop the trials was based on a recommendation for futility from an Independent Data Monitoring Committee (IDMC) following a pre-specified interim analysis.
Efgartigimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified during the studies.
ARGENX plans to conduct a comprehensive analysis of the data to gain insights for future research in TED, with results to be shared at a future medical meeting.

Dec 15, 2025, 11:15 AM

6-K

argenx Announces Strong Q3 2025 Financial Results with VYVGART Sales Exceeding $1 Billion

ARGX

Earnings

Product Launch

New Projects/Investments

argenx reported Q3 2025 total product net sales of $1.13 billion, marking the first time VYVGART sales surpassed $1 billion in a single quarter, representing 96% year-over-year growth.
U.S. product net sales for VYVGART reached $964 million, growing 20% quarter-over-quarter, primarily driven by the successful launch of the pre-filled syringe (PFS) and continued momentum in gMG and CIDP.
The company achieved an operating profit of $346 million and a profit after tax of $344 million for the quarter, with a cash balance of $4.3 billion at quarter-end.
argenx is expanding its pipeline, with three first-in-class molecules in Phase 3 development and plans for four new molecules in Phase 1 development by year-end 2025.
Positive ADAPT SERUM study results support a planned label expansion for VYVGART to include all three seronegative gMG subgroups, indicating a significant commercial opportunity.

Oct 30, 2025, 12:30 PM

Transcript

argenx Reports Record Q3 2025 Financial Results and Pipeline Progress

ARGX

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

argenx reported record total product net sales of $1.13 billion in Q3 2025, marking the first time VYVGART sales surpassed $1 billion in a single quarter, representing 19% quarter-over-quarter growth and 96% year-over-year growth.
The pre-filled syringe (PFS) formulation of VYVGART is a key growth driver, contributing to a 20% quarter-over-quarter increase in U.S. sales and attracting over 260 new prescribers since its launch.
The company has three first-in-class molecules in Phase III development and expects five registration readouts in 2026, including for Ocular gMG, Myositis, TED, MMN, and ITP.
Positive results from the ADAPT SERON study support a planned label expansion for VYVGART to include all three seronegative gMG subgroups.
argenx ended the quarter with a strong cash balance of $4.3 billion and expects full-year 2025 operating expenses to be between $2.6 billion and $2.7 billion.

Oct 30, 2025, 12:30 PM

Transcript

argenx Reports Strong Q3 2025 Financial Results and Pipeline Advancements

ARGX

Earnings

Product Launch

Guidance Update

argenx reported Q3 2025 total product net sales of $1.13 billion, a 96% year-over-year increase, marking the first time VYVGART sales exceeded $1 billion in a single quarter.
The pre-filled syringe (PFS) formulation of VYVGART is a key growth driver, with over 50% of new patients starting on PFS and expanding the prescriber base.
The company plans to file for a label expansion for seronegative generalized Myasthenia Gravis (gMG) following positive ADAPT SERUM study results and anticipates five registration readouts in 2026 across its pipeline.
Strategic pipeline adjustments include advancing efgartigimod into Phase 3 for Graves disease while discontinuing development for empasiprubart in dermatomyositis and efgartigimod in lupus nephritis.
argenx concluded Q3 2025 with a cash balance of $4.3 billion and projects full-year combined R&D and SG&A expenses between $2.6 billion and $2.7 billion.